BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors
A broad spectrum of tumors develop resistance to classic chemotherapy, necessitating the discovery of new therapies. One successful strategy exploits the synthetic lethality between poly(ADP-ribose) polymerase 1/2 proteins and DNA damage response genes, including BRCA1, a factor involved in homologo...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IOS Press
2017-10-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428317727479 |